JO3262B1 - توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان - Google Patents

توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان

Info

Publication number
JO3262B1
JO3262B1 JOP/2010/0108A JOP20100108A JO3262B1 JO 3262 B1 JO3262 B1 JO 3262B1 JO P20100108 A JOP20100108 A JO P20100108A JO 3262 B1 JO3262 B1 JO 3262B1
Authority
JO
Jordan
Prior art keywords
decitabine
combination
cancer
deamiase
cytidine
Prior art date
Application number
JOP/2010/0108A
Other languages
English (en)
Inventor
Duvall Bridget
Hamiltion Gregory
Ferraris Dana
Belyakov Sergei
Vaal Mark
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3262B1 publication Critical patent/JO3262B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بطرق لعلاج السرطان تشتمل على اعطاء ديسيتابين بالاشتراك مع مركبات تعمل على تثبيط نزع مجموعة الأمين للانزيم المسئول عن تثبيط ديسيتابين.
JOP/2010/0108A 2009-04-06 2010-04-06 توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان JO3262B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16711909P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
JO3262B1 true JO3262B1 (ar) 2018-09-16

Family

ID=42357480

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0108A JO3262B1 (ar) 2009-04-06 2010-04-06 توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان

Country Status (11)

Country Link
US (1) US8329666B2 (ar)
EP (1) EP2416780B1 (ar)
JP (1) JP5730854B2 (ar)
AR (1) AR076263A1 (ar)
AU (1) AU2010234641B2 (ar)
CA (1) CA2757744C (ar)
ES (1) ES2628580T3 (ar)
JO (1) JO3262B1 (ar)
TW (1) TWI503121B (ar)
UY (1) UY32546A (ar)
WO (1) WO2010118010A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2870937B2 (ja) 1990-02-26 1999-03-17 凸版印刷株式会社 金属蒸着フィルムの製造方法
JO2778B1 (ar) 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
EP2417146B1 (en) * 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
CN113613651B (zh) * 2019-03-29 2025-08-12 诺沃库勒有限责任公司 用PTGER3抑制剂恢复TTField抗性癌细胞中对TTField的敏感性的方法
CN118354759A (zh) 2021-10-19 2024-07-16 阿基拉比奥有限公司 包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3481172D1 (de) 1983-10-26 1990-03-08 Sheldon B Greer Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung.
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
WO1994019362A1 (en) 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN100368422C (zh) 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
WO2002094844A2 (en) 2001-05-18 2002-11-28 Rakesh Kumar Antiviral nucleosides
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
EP1819718A1 (en) 2004-12-08 2007-08-22 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (ar) 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
ES2628609T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
EP2417146B1 (en) * 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer

Also Published As

Publication number Publication date
TW201102072A (en) 2011-01-16
TWI503121B (zh) 2015-10-11
EP2416780A1 (en) 2012-02-15
AU2010234641A1 (en) 2011-11-10
UY32546A (es) 2010-10-29
JP2012522841A (ja) 2012-09-27
WO2010118010A1 (en) 2010-10-14
CA2757744C (en) 2018-02-13
JP5730854B2 (ja) 2015-06-10
ES2628580T3 (es) 2017-08-03
AR076263A1 (es) 2011-06-01
US8329666B2 (en) 2012-12-11
EP2416780B1 (en) 2017-03-08
US20100279967A1 (en) 2010-11-04
CA2757744A1 (en) 2010-10-14
AU2010234641B2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
UY32546A (es) Composiciones y metodos para tratar cancer
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
SG10201811480WA (en) Therapeutic compounds and compositions
MY160041A (en) Compositions and methods for treating parasitic infections
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
NI201200090A (es) Composiciones para tratar náusea y vómito centralmente mediados
MX2010006991A (es) Tratamientos de cancer terapeuticos.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
GB0920703D0 (en) Compositions containing satiogens and methods of use
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
TNSN08481A1 (en) Pyrrolopyrimidine compounds and their uses
TW200612918A (en) Lonidamine analogs
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
MX2012004741A (es) Apremilast para el tratamiento de sarcoidosis.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
TN2011000482A1 (en) Organic compounds and their uses
TNSN08400A1 (en) Organic compounds and their uses
PH12014501639A1 (en) Pharmaceutical compositions and methods
IL207310A0 (en) Vaccine compositions
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.
WO2009114703A3 (en) Combination therapy for the treatment of cancer